洛铂联合伊立替康治疗广泛期小细胞肺癌的临床观察

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (9): 1049-1052.

洛铂联合伊立替康治疗广泛期小细胞肺癌的临床观察

肖晓光, 陈元

华中科技大学同济医学院附属同济医院肿瘤科,武汉 430030,湖北

收稿日期:2012-12-18 修回日期:2013-05-23 发布日期:2013-09-07
通讯作者: 陈元,男,博士,主任医师,教授,研究方向:肺癌的综合治疗。Tel: 13986126963 E-mail: chenyuan008@163.com
作者简介:肖晓光,男,硕士,主治医师,研究方向:肺癌的综合治疗。Tel: 13986041392 E-mail: xiaoxg997@yahoo.com.cn

Clinical observation of Lobaplatin combined with Irinotecan in the treatment of extensive-stage disease small-cell lung cancer

XIAO Xiao-guang, CHEN Yuan

Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, Hubei, China

Received:2012-12-18 Revised:2013-05-23 Published:2013-09-07

摘要/Abstract

摘要： 目的: 评价洛铂联合伊立替康治疗广泛期小细胞肺癌的临床疗效和安全性。方法: 洛铂 35 mg/m²第1天,伊立替康 80 mg/m²第1、8天,每 21 d 为一周期,每2个周期结束复查影像学资料行疗效评价,治疗既往未接受过化疗的广泛期小细胞肺癌25例。结果: 25例患者均可评价疗效,完全缓解(CR)1例,部分缓解(PR)9例,稳定(SD)7例,进展(PD)8例。客观缓解率(ORR) 40%, 疾病控制率(DCR) 68%, 中位无进展生存期(PFS)5.3 个月,中位生存期(OS) 7.6 个月,主要毒副反应为血液学毒性及消化道反应。结论: 洛铂联合伊立替康方案作为广泛期SCLC化疗有较好的疗效,毒副反应可以耐受。

关键词: 小细胞肺癌, 洛铂, 伊立替康

Abstract: AIM: To investigate the effects and side effects of Lobaplatin plus Irinotecan regimens in the treatment of patients suffered from extensive stage disease small-cell lung cancer (ED-SCLC).METHODS: 25 patients suffered from ED-SCLC were treated by Lobaplatin 35 mg/m² i.v.d1 plus Irinotecan 80 mg/m2 i.v.d1,8, every 3 weeks. Efficacy was estimated by imaging every 2 cycles.RESULTS: In 25 evaluable patients,CR was 4% (1/25),PR was 36% (9/25), SD was 28%(7/25), and PD was 32% (8/25). The objective response rate(ORR)was 40% . The disease control rate (DCR) was 68%. The median progression free survival (PFS) was 5.3 months. The median overall survival(OS) was 7.6 months. The most commonly seen adverse events(AEs) were myelosuppression and diarrhea. There was no treatment-related death.CONCLUSION: The treatment of Lobaplatin plus Irinotecan shows an effective antitumor activity and a favorable toxicity profile in patients with ED-SCLC.

Key words: Small-cell lung cancer, Lobaplatin, Irinotecan

中图分类号:

R734.2

肖晓光, 陈元. 洛铂联合伊立替康治疗广泛期小细胞肺癌的临床观察[J]. 中国临床药理学与治疗学, 2013, 18(9): 1049-1052.

XIAO Xiao-guang, CHEN Yuan. Clinical observation of Lobaplatin combined with Irinotecan in the treatment of extensive-stage disease small-cell lung cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(9): 1049-1052.

参考文献

[1] Patel S, Macdonald OK, Suntharalingam M. Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer[J]. Cancer, 2009, 115(4): 842-850.
[2] Tsuchiya R, Suzuki K, Ichinose Y, et al. PhaseⅡtrial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-Ⅲa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101)[J]. J Thorac Cardiovasc Surg, 2005, 129(5): 977-983.
[3] Schmittel A. Second-line therapy for small-cell lung cancer[J]. Expert Rev Anticancer Ther,2011,11(4):631-637.
[4] Simon M, Argiris A, Murren JR. Progress in the therapy of small cell lung cancer[J]. Crit Rev Oncol Hematol, 2004, 49(2): 119-133.
[5] Nogami N, Kiura K, Takigawa NS, et al. A phaseⅡtrial of combination chemotherapy with topotecan and amrubicin in small cell lung cancer (SCLC) [J]. J Clin Oncol, 2010, 28(15 Suppl):a7054.
[6] Okamoto H, Watanabe K, Nishiwaki Y, et al. PhaseⅡstudy of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small cell lung cancer[J]. J Clin Oncol,1999, 17(11): 3540-3545.
[7] Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer[J]. N Engl J Med, 2002, 346(2): 85-91.
[8] Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase Ⅲ trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer[J].J Clin Oncol,2006, 24(13): 2038-2043.
[9] Natale RB, Lara PN, Chansky K, et al. S0124: A randomized Phase Ⅲ trial comparing irinotecan/cisplatin(IP) with etoposide/cisplatin (EP) in patients with previously untreated extensive stage small cell lung cancer (E-SCLC) [J]. J Clin Oncol, 2008, 26(Suppl): a7512.
[10] Schmittel A, Fischer vonWeikersthal L, Sebastian M, et al. A randomized phase Ⅱ trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer[J]. Ann Oncol, 2006,17(4): 663-667.
[11] Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase Ⅲ trial[J]. J Clin Oncol, 2008, 26(26): 4261-4267.
[12] 赖树清.抗肿瘤药物洛铂[J].世界临床药物,2005,26(5):365.
[13] Fiebig HH,Henb H, Vonpawel I, et al. PhaseⅡclinical trial of lobaplatin (D-19466) in pretreated patients with small-cell lung cancer[J]. Onkologie, 1996, 19: 328-332.
[14] 蒋侃,黄诚,吴标,等.伊立替康联合洛铂治疗复发广泛期小细胞肺癌临床观察[J].中国实用医药,2011,6(6):61-63.
[15] 徐舒,马振,赵永心,等,洛铂联合伊立替康治疗复治性小细胞肺癌的临床研究[J]. 临床肿瘤学杂志,2010,15(7):640-642.